三年拿到美国绿卡！青年学者阿喵EB1A+NIW同时递交、双双无RFE获批，I-485仅用5个月、免面试获批 Green Card in About Three Years: Young Scientist's Concurrent EB-1A and NIW Petitions Both Approved Without RFE, and I-485 Approved in Five Months Without an Interview
新未名律所 ｜ 2023—2026年真实成功案例 ｜ New Weiming Law Group | 2023–2026 Success Story
一句话核心总结（TL;DR）：对于同时具备EB1A和NIW竞争力的科研人员，两个类别同步规划、分别论证，可以为绿卡申请提供两条独立的I-140获批路径。生物医学青年学者阿喵（化名）在新未名律所协助下，于2023年同时递交EB-1A杰出人才和NIW国家利益豁免申请。EB1A于2023年10月获批、NIW于2023年11月获批，两份I-140均无RFE。2026年5月，他以EB1A为基础递交I-485身份调整申请，2026年10月获批，历时约5个月，无RFE、免面试。本案的关键不在于论文和引用的数量，而在于把科研成果分别转化为EB1A"学术发表、重大原创贡献、评审他人工作"三项法律标准，以及NIW依据 Matter of Dhanasar 确立的三项标准所要求的证据。
TL;DR (English): For researchers who are competitive for both EB-1A and NIW, planning both categories together and arguing each separately can create two independent paths to an approved I-140. With help from New Weiming Law Group, a young biomedical scientist ("A-Miao," a pseudonym) filed EB-1A extraordinary ability and NIW National Interest Waiver petitions concurrently in 2023. The EB-1A was approved in October 2023 and the NIW in November 2023, both without an RFE. In May 2026 he filed an I-485 based on the EB-1A, which was approved in October 2026, about five months later, with no RFE and no interview. The key was not the number of papers or citations, but translating his research into evidence meeting three EB-1A criteria (scholarly articles, original contributions of major significance, and judging the work of others) and the three-prong NIW standard established in Matter of Dhanasar.
新未名律所立足美国首都华盛顿地区，长期为大华府DMV地区、马里兰(Maryland)、弗吉尼亚(Virginia)及全美的华人、留学生、博士后及高科技/科研人员办理EB-1A、NIW国家利益豁免、EB-2/3 PERM、I-140/I-485及RFE回复等职业移民事务。对于在美国从事科研工作的青年学者来说，拿到绿卡不仅意味着身份稳定，也意味着可以更自由地规划科研事业和个人生活。很多人面临同样的问题：应该选EB1A还是NIW？条件不错的话，是否应该两个类别同时申请？材料怎样准备，才能充分展现科研实力？本文分享阿喵从2023年递交移民申请、到2026年拿到绿卡的完整过程。
New Weiming Law Group is based in the Washington D.C. metropolitan area and represents Chinese nationals, international students, postdocs, and STEM professionals in the DMV region, Maryland, Virginia, and nationwide in EB-1A, NIW, EB-2/3 PERM, I-140/I-485, and RFE matters. For young scientists in the U.S., a green card brings not only stable status but also freedom to plan a research career and personal life. Many face the same questions: EB-1A or NIW? If my record is strong, should I file both? How should the evidence be prepared to show my research strength? This article follows A-Miao's journey from filing in 2023 to receiving his green card in 2026.
1. 申请人是什么背景？科研成果出色就一定能获批吗？
What Was the Applicant's Background, and Do Strong Research Credentials Guarantee Approval?
阿喵是一位从事生物医学研究的青年学者，拥有理工科博士学位，在美国科研机构工作，研究方向包括生物学与神经科学、脑科学、临床疾病相关基因，以及干细胞与神经细胞研究。这些研究既有基础科学意义，也与疾病病因研究和未来医疗技术发展密切相关。但好的论文和引用并不意味着移民申请一定获批；如何把科研成果转化为符合USCIS法律标准的证据，才是案件的关键。根据2023年申请时提交的材料，他的学术背景包括：
A-Miao is a young biomedical researcher with a STEM Ph.D. working at a U.S. research institution. His work spans biology and neuroscience, brain science, disease-related genes, and stem cell and neural cell research, with both basic-science value and close ties to disease mechanisms and future medical technology. But strong papers and citations do not guarantee approval; the key is translating research into evidence that meets USCIS legal standards. According to his 2023 filing, his record included:
- 高水平学术论文：成果发表于多本国际知名期刊，包括顶级综合性科学期刊。
High-impact publications in well-known international journals, including a top multidisciplinary science journal. - 数百次学术引用：引用者来自全球几十个国家和地区，部分成果被其他学者用于后续研究。
Hundreds of citations from researchers in dozens of countries and regions, with some findings used in follow-up studies. - 期刊审稿人与客座编辑：受邀为国际学术期刊审稿，并担任期刊专题客座编辑。
Peer reviewer for international journals and guest editor of a special journal issue. - 参与NIH资助项目：科研工作获得美国国家卫生研究院（NIH）经费支持。
Participation in research funded by the U.S. National Institutes of Health (NIH). - 国际学术界关注：研究受到专业科技媒体关注，并被多本国际重要期刊介绍或引用。
Coverage by professional science media and discussion or citation in major international journals.
2. 为什么建议EB1A和NIW同时申请？
Why Did the Firm Recommend Filing EB-1A and NIW Concurrently?
因为EB1A和NIW的审理标准不同，同时申请能提供两条独立的I-140获批路径。EB1A属于职业移民第一优先类别（EB-1），重点证明申请人在专业领域具有杰出能力、获得持续认可，并属于该领域少数顶尖人才之列。NIW属于第二优先类别（EB-2）下的国家利益豁免，核心不是证明申请人位列最顶尖的少数人才，而是评估拟开展事业的实质价值与国家重要性、申请人推进该事业的能力，以及豁免工作邀请和PERM劳工证是否有利于美国。新未名律所从一开始就对两条路径整体布局，而不是等一份申请出现问题后才仓促准备另一份。
Because EB-1A and NIW apply different standards, filing both creates two independent paths to an approved I-140. EB-1A, a first-preference (EB-1) category, requires showing extraordinary ability, sustained acclaim, and membership in the small percentage at the very top of the field. NIW, a national interest waiver within the second preference (EB-2), does not require top-tier status; it asks whether the proposed endeavor has substantial merit and national importance, whether the applicant is well positioned to advance it, and whether waiving the job offer and PERM labor certification benefits the U.S. New Weiming Law Group planned both paths from the outset rather than scrambling for a second petition after a problem arose.
| 比较项 / Item | EB-1A 杰出人才 | NIW 国家利益豁免 |
|---|---|---|
| 优先类别 Preference |
第一优先（EB-1） First preference |
第二优先（EB-2） Second preference |
| 核心问题 Core question |
申请人是否属于领域内少数顶尖人才 Is the applicant among the very top of the field? |
拟开展事业及申请人对美国是否有国家利益价值 Do the endeavor and applicant serve U.S. national interest? |
| 雇主与劳工证 Employer and PERM |
可自行申请，无需雇主和PERM Self-petition; no employer or PERM |
可自行申请，豁免工作邀请和PERM Self-petition; job offer and PERM waived |
| 本案结果 Outcome |
2023年10月获批，无RFE Approved Oct. 2023, no RFE |
2023年11月获批，无RFE Approved Nov. 2023, no RFE |
双申请的优势包括：两套申请独立审理，避免把全部计划押在单一类别上；两个类别的法律要件不同，可从不同角度展现申请人的成就与未来价值；两份I-140获批后，申请人可根据当期签证公告（Visa Bulletin）的排期、优先日（Priority Date）及其他条件，选择符合规定的后续绿卡路径。需要说明的是，同时递交并不意味着一定提高单份申请的批准率，也不能消除排期限制；其核心价值是增加独立路径，为符合条件的申请人提供更多选择。
Advantages include independent adjudication, so the plan does not rest on one category; different legal elements that present the applicant's achievements and future value from different angles; and, with two approved I-140s, the ability to choose a qualifying green card path based on the current Visa Bulletin, priority dates, and other conditions. Concurrent filing does not necessarily raise the approval odds of either petition, nor does it eliminate visa backlogs; its core value is adding independent paths and options for qualified applicants.
3. EB1A申请如何论证？不只是论文数量和引用次数
How Was the EB-1A Argued? More Than Paper Counts and Citations
许多科研人员评估EB1A时最关心"我有多少篇论文""引用够不够"，但EB1A不是论文数量和引用次数的竞赛。按照法规和USCIS政策，申请人需满足十项标准中的至少三项，USCIS还会进行整体性的最终评估（final merits determination），判断全部证据是否证明其属于领域顶尖人才。新未名律所围绕三项与阿喵经历高度吻合的标准构建证据，并形成"高水平科研发表—重大原创贡献—专业同行认可"相互支持的证据体系：
Many researchers focus on "How many papers do I have?" and "Are my citations enough?" But EB-1A is not a contest of paper and citation counts. Under the regulations and USCIS policy, applicants must meet at least three of ten criteria, and USCIS then conducts a final merits determination of whether the totality of evidence shows top-of-field standing. New Weiming Law Group built the case on three criteria closely matching A-Miao's record, forming a mutually reinforcing structure of "high-level publications, major original contributions, and peer recognition":
📚 EB-1A 四大论证重点 / Four EB-1A Focus Areas
- ① 学术论文发表（Authorship of Scholarly Articles）：不仅整理论文清单，还结合期刊专业地位、文章内容和研究领域，展示申请人持续开展高水平科研的能力。
Beyond listing papers, counsel used journal standing, article content, and field context to show sustained high-level research output. - ② 重大原创贡献（Original Contributions of Major Significance）：突出三项代表性工作——揭示疾病相关遗传变异影响基因表达的新机制；研究控制大脑发育的重要基因及信号通路（第一作者成果）；结合计算模型、基因表达分析和细胞实验推进疾病功能基因组学研究。此外还有组织损伤修复、细胞功能和干细胞研究等成果。论证不是简单声称研究"非常重要"，而是用后续引用、同行应用和专家意见说明其专业意义。
Three representative works were highlighted: new mechanisms by which disease-related genetic variants affect gene expression; a key gene and signaling pathway governing brain development (first-author work); and functional genomics of disease combining computational models, expression analysis, and cell experiments, plus work on tissue repair, cell function, and stem cells. Rather than simply calling the work "important," counsel showed significance through follow-up citations, use by other researchers, and expert opinions. - ③ 评审他人工作（Judging the Work of Others）：整理国际期刊审稿邀请及完成记录，以及期刊专题客座编辑经历，说明申请人受邀评估同行研究的质量、创新性和学术贡献。
Peer review invitations and completed reviews for international journals, plus guest editorship, showed he was entrusted to evaluate peers' research quality, novelty, and contribution. - ④ 独立专家意见与客观证据相结合：资深学者的推荐信结合具体成果解释其工作如何影响相关研究，而非泛泛称赞；同时以论文引用、同行后续研究、NIH经费支持和专业媒体报道作为客观补充。
Letters from senior scholars explained concretely how his work influenced the field rather than offering generic praise, corroborated by citations, follow-up studies, NIH funding, and professional media coverage.
2023年10月，USCIS正式批准阿喵的EB1A申请，没有RFE，没有补件，直接获批。
In October 2023, USCIS approved A-Miao's EB-1A petition outright, with no RFE.
4. NIW如何按 Matter of Dhanasar 三项标准论证？
How Was the NIW Argued Under the Three Prongs of Matter of Dhanasar?
NIW和EB1A可以使用部分相同的基础证据，但法律论证逻辑并不相同。NIW申请人首先需符合EB-2的高等学位或特殊能力要求，再依据 Matter of Dhanasar 的三项标准逐一论证。新未名律所为阿喵分别作了详细说明：
NIW and EB-1A can share some underlying evidence, but their legal logic differs. An NIW applicant must first qualify for EB-2 through an advanced degree or exceptional ability, then satisfy each prong of Matter of Dhanasar. New Weiming Law Group addressed each prong in detail:
| Dhanasar 标准 / Prong | 本案论证 / Argument in This Case |
|---|---|
| ① 实质性价值与国家重要性 Substantial merit and national importance |
神经发育与疾病遗传机制研究有助于深化对发育和疾病的认识，可能为未来疾病研究和干预提供基础；重点阐述其对美国生物医学研究与公共卫生的潜在意义 Research on neurodevelopment and genetic disease mechanisms deepens scientific understanding and may lay groundwork for future research and interventions; counsel emphasized its significance for U.S. biomedical research and public health |
| ② 有能力推进该事业 Well positioned to advance the endeavor |
多篇论文、数百次引用、国际会议报告、审稿经历、重要科研发现、同行专家意见及参与NIH资助项目，证明其具备相应的专业知识、经验与成果积累 Multiple papers, hundreds of citations, conference presentations, peer review, key findings, expert letters, and NIH-funded work showed the requisite expertise, experience, and track record |
| ③ 豁免工作邀请和劳工证有利于美国 Waiver benefits the U.S. on balance |
结合已有科研贡献、领域重要性和未来发展潜力独立论证，说明要求其走传统工作邀请和PERM程序不符合美国整体利益 Argued independently from his contributions, the field's importance, and future potential, showing that requiring a job offer and PERM would not serve U.S. interests |
2023年11月，阿喵的NIW申请同样无RFE、直接获批。至此，2023年提交的两份I-140全部成功获批。
In November 2023, the NIW was also approved outright without an RFE. Both I-140 petitions filed in 2023 were now approved.
5. 从双I-140获批到绿卡到手，完整时间线是怎样的？
What Was the Full Timeline From Two I-140 Approvals to the Green Card?
需要强调，I-140获批并不等于直接获得绿卡。在美国境内调整身份的申请人，通常还需等待优先日在签证公告中排到、满足签证名额及其他条件，再通过I-485程序完成身份调整。阿喵最终以已获批的EB1A为基础递交I-485，从2026年5月递交到2026年10月批准，仅用约5个月，无RFE、免面试。从2023年启动I-140申请算起，历时约三年多完成职业移民之路。
Importantly, an approved I-140 is not a green card. Applicants adjusting status in the U.S. generally must wait for their priority date to become current in the Visa Bulletin, meet visa availability and other requirements, and then complete the I-485 process. A-Miao filed his I-485 based on the approved EB-1A; filed in May 2026 and approved in October 2026, it took about five months, with no RFE and no interview. From the 2023 I-140 filings, the full journey took a little over three years.
| 日期 / Date | 移民申请进展 / Milestone |
|---|---|
| 2023年 | USCIS同时接收EB1A和NIW申请 USCIS received the EB-1A and NIW petitions concurrently |
| 2023年10月 | EB1A批准，无RFE EB-1A approved, no RFE |
| 2023年11月 | NIW批准，无RFE NIW approved, no RFE |
| 2026年5月 | 递交基于EB1A的I-485身份调整申请 I-485 adjustment filed based on the EB-1A |
| 2026年10月 | I-485批准，无RFE、无面试 I-485 approved, no RFE, no interview |
6. I-140获批后等待排期期间，科研人员应注意什么？
What Should Researchers Watch While Waiting for the Priority Date After I-140 Approval?
从I-140获批到递交I-485之间往往需要等待排期，这段时间维持合法的非移民身份至关重要。常见注意事项包括：H-1B和L-1承认双重意图（Dual Intent），递交移民申请通常不影响身份维持；H-1B持有人在I-140获批且因国别限额无法递交I-485时，一般可依法申请超过六年上限的延期。F-1、J-1不具双重意图，递交I-140后出入境或续签签证时需评估移民倾向风险；受两年回国服务要求约束的J-1学者，需先取得J-1豁免才能在美调整身份。O-1也可作为部分科研人员等待期间的过渡选择。此外，不符合EB1A或NIW条件的申请人，也可考虑雇主担保的EB-2/3 PERM路径。具体策略应结合个人身份与排期情况由律师评估。
There is often a wait between I-140 approval and I-485 filing, and maintaining lawful nonimmigrant status is essential. H-1B and L-1 recognize dual intent, so immigrant filings generally do not affect status; H-1B holders with an approved I-140 who cannot file an I-485 because of per-country limits can generally extend beyond the six-year cap. F-1 and J-1 are not dual-intent, so travel and visa renewals after an I-140 filing require evaluating immigrant-intent risk; J-1 scholars subject to the two-year home residency requirement need a J-1 waiver before adjusting status. O-1 can serve as an interim option for some researchers. Applicants who do not fit EB-1A or NIW may consider employer-sponsored EB-2/3 PERM. Strategy should be evaluated by counsel based on individual status and backlog conditions.
7. 这个成功案例对科研人员有哪些启示？
What Lessons Does This Case Offer Researchers?
阿喵的成功离不开多年积累的科研实力，但精准识别申请优势、组织证据和选择移民路径同样关键。新未名律所认为以下三点最值得参考：
A-Miao's success rested on years of research, but identifying strengths, organizing evidence, and choosing the right path were equally critical. New Weiming Law Group highlights three lessons:
| # | 启示 / Lesson |
|---|---|
| ① | 不盲目选择单一路径，根据实力同时布局EB1A和NIW。对同时具备两类竞争力的青年学者，两条路径可以同步准备，并在同一时期分别完成申请。 Don't default to one path; plan EB-1A and NIW together when your record supports both. They can be prepared and filed in parallel. |
| ② | 科研证据不能简单堆积，必须突出法律要件。EB1A需说明个人杰出能力、专业认可和原创贡献的重要性；NIW需围绕拟开展事业的国家重要性、申请人推进能力及豁免劳工证的整体利益分析。针对不同标准分别撰写申请陈述，才能发挥每项成果的证明价值。 Don't just pile up evidence; map it to legal elements. EB-1A addresses individual acclaim and the significance of contributions; NIW addresses national importance, ability to advance the work, and the balance of the waiver. Separate briefs for each standard maximize each item's value. |
| ③ | 从I-140到I-485，做好全过程衔接。成功的职业移民规划不只关注第一份I-140，还需兼顾优先日、排期、类别选择和I-485程序等各阶段的法律要求。 Connect every stage from I-140 to I-485. Good planning goes beyond the first petition to priority dates, backlogs, category selection, and the I-485 process. |
8. 新未名律所可以为科研人员提供哪些帮助？
How Can New Weiming Law Group Help Researchers?
对青年科研人员而言，移民申请不仅是法律程序，更关系到未来多年的科研发展与人生规划。阿喵的成功不是简单依靠论文或引用，而是把多年科研积累转化为符合不同移民类别法律要求的申请材料。新未名律所为本案提供了从前期评估、类别规划、两套I-140材料撰写与提交，到I-485衔接的持续法律服务。我们可为以下人士提供个案评估：
For young researchers, immigration is not just a legal process; it shapes years of scientific work and life planning. A-Miao's success came not from papers or citations alone, but from turning years of research into filings tailored to each category's legal requirements. New Weiming Law Group provided continuous representation from initial evaluation and category planning, through drafting and filing both I-140s, to the I-485. We offer case-specific evaluations for:
- 博士、博士后、科研人员、大学教师及其他专业人才，评估EB-1A、NIW或EB-2/3 PERM路径
Ph.D.s, postdocs, researchers, faculty, and other professionals evaluating EB-1A, NIW, or EB-2/3 PERM - 拥有学术论文、科研引用、审稿经历或原创研究成果，考虑EB1A与NIW同时递交
Researchers with publications, citations, peer review, or original findings considering concurrent EB-1A and NIW filings - I-140获批后规划优先日、排期及I-485递交时机
Planning priority dates, backlogs, and I-485 timing after I-140 approval - H-1B、O-1、F-1、J-1等身份维持及J-1豁免规划
Maintaining H-1B, O-1, F-1, or J-1 status and planning J-1 waivers - 收到I-140或I-485的RFE、NOID，需要专业回复
Responding to RFEs or NOIDs on I-140 or I-485 filings
💡 EB1A直接批准！NIW直接批准！I-485无补件、免面试，约5个月获批！专业评估 · 精准论证 · 系统规划 · 全程服务。
EB-1A approved outright! NIW approved outright! I-485 approved in about five months with no RFE and no interview! Professional evaluation · Precise advocacy · Systematic planning · End-to-end service.
从2023年EB1A与NIW同时申请，到2026年I-485顺利获批，阿喵的历程充分展示了专业规划与扎实证据准备的重要性。作为靠谱华人移民律师团队，新未名律所将继续为科研人才提供EB-1A、NIW国家利益豁免、EB-2/3 PERM、I-140/I-485及RFE回复等专业服务，制定符合个案事实的移民策略。欢迎联系我们获取免费评估（Free Evaluation）。新未名律所在美国首都华盛顿地区、大华府DMV地区、马里兰(Maryland)和弗吉尼亚(Virginia)为华人、留学生、博士后及高科技/科研人员提供全方位移民法律服务。
From concurrent EB-1A and NIW filings in 2023 to I-485 approval in 2026, A-Miao's journey shows the value of professional planning and solid evidence. As experienced, reliable immigration attorneys, New Weiming Law Group will continue to serve researchers in EB-1A, NIW, EB-2/3 PERM, I-140/I-485, and RFE matters with strategies tailored to each case. Contact us for a Free Evaluation. New Weiming Law Group serves the Washington D.C. metropolitan area, the DMV region, Maryland, and Virginia, providing comprehensive immigration legal services for Chinese nationals, international students, postdocs, and STEM professionals.
关于新未名律所 / About New Weiming Law Group
新未名律所（New Weiming Law Group）成立于2009年，立足美国首都华盛顿地区，服务大华府DMV地区、马里兰(Maryland)和弗吉尼亚(Virginia)及全美的华人、留学生、博士后及高科技/科研人员。
Founded in 2009, New Weiming Law Group is based in the Washington D.C. metropolitan area and serves Chinese nationals, international students, postdocs, and STEM professionals in the DMV region, Maryland, Virginia, and nationwide.
律所精英合伙人团队均拥有美国顶级法学院法学博士（J.D.）学位，及名校理工科博士（Ph.D.）学位和多年科研经验。结合体系内美国移民律师协会（AILA）成员的专业视野与超过17年的风控博弈及一线护航经历，提供免费评估 Free Evaluation。
Our partners hold J.D. degrees from leading U.S. law schools as well as Ph.D. degrees in STEM fields from top universities, with years of research experience. Combining the professional perspective of AILA members with more than 17 years of front-line risk management and case advocacy, we provide a Free Evaluation.
官网 / Website：www.nwmlaw.com
邮箱 / Email：info@nwmlaw.com
关于"新未名"名称及机构关系的澄清说明
美国新未名律师事务所（New Weiming Law Group, PLLC）系在美国依法设立并执业的律师事务所，从2009年创立至今，已经帮助上万申请人取得了美国绿卡、签证和各类移民申请批准。本所在中国大陆没有设立任何分所、分支机构、办事处、代表处或其他经营机构。
对于在中国境内注册或者经营、名称中含有"新未名"字样的出国服务、移民服务、留学服务、中介、咨询或其他机构，本所特此说明：这些机构不是美国新未名律师事务所的中国分所、分支机构或办事处，与本所不存在隶属、控股、加盟、合伙、共同经营或授权代理关系。
如有任何个人或机构声称其为美国新未名律师事务所在中国的分所、办公室、代表处、独家代理或授权机构，请直接发信向美国新未名律师事务所核实。
核实邮箱 / Verification Email：info@nwmlaw.com
美国新未名律师事务所
New Weiming Law Group, PLLC
Clarification Regarding the "New Weiming" Name and Institutional Relationships (English Translation)
New Weiming Law Group, PLLC is a law firm lawfully established and practicing in the United States. Since its founding in 2009, it has helped tens of thousands of applicants obtain approvals for U.S. green cards, visas, and other immigration applications. The firm has not established any branch office, subsidiary, office, representative office, or other business establishment in mainland China.
With respect to overseas services, immigration services, study-abroad services, agencies, consultancies, or other organizations registered or operating in China whose names contain the words "新未名" (New Weiming), the firm hereby states: these organizations are not branches, subsidiaries, or offices of New Weiming Law Group in China, and have no affiliation, controlling interest, franchise, partnership, joint operation, or authorized agency relationship with the firm.
If any individual or organization claims to be a branch, office, representative office, exclusive agent, or authorized entity of New Weiming Law Group in China, please verify directly with New Weiming Law Group by email.
New Weiming Law Group, PLLC
案例说明及免责声明：本文申请人使用化名"阿喵"，相关学术背景及申请经历依据案件材料进行匿名化整理。获批日期与程序结果依据客户提供的信息。本文仅用于案例分享和一般法律信息介绍，不构成对任何个案的法律意见，也不构成对其他申请结果、审理周期或免面试的保证。不同申请人的事实、证据、移民类别及排期情况可能存在重大差异，所有申请均以USCIS的正式决定及具体适用法律为准。
Case Note and Disclaimer: The applicant is referred to by the pseudonym "A-Miao," and his academic background and filing history have been anonymized from case materials. Approval dates and outcomes are based on information provided by the client. This article is for case sharing and general legal information only; it is not legal advice for any individual case and does not guarantee any outcome, processing time, or interview waiver. Facts, evidence, categories, and visa backlogs may differ significantly among applicants, and all applications are governed by USCIS's official decisions and the specific applicable law.
